In this context, our data suggest that the pharmacologic targeting of YAP/TAZ-TEAD transcriptional signaling with benzoporphyrin derivatives or allosteric inhibitors [71,72] may synergize with agonists of apoptotic TRAIL receptors to overcome the TRAIL resistance of tumor cells. Here, TNFSF10 is linked to neoplasm.